144 related articles for article (PubMed ID: 30845851)
61. Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study.
Xie S; Yu Y; Liu Y; Zhang S; Yuan S; Fan K; Tang B; Zhou Q; Sun Y; Liu R; Cao D; Chen Y; Wang Y; Liu G; Ma H; Tao C; Zeng L; Zhong L
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431337
[TBL] [Abstract][Full Text] [Related]
62. Comparison study of computed tomography-guided radiofrequency and microwave ablation for pulmonary tumors: A retrospective, case-controlled observational study.
Chi J; Ding M; Shi Y; Wang T; Cui D; Tang X; Li P; Zhai B
Thorac Cancer; 2018 Oct; 9(10):1241-1248. PubMed ID: 30070054
[TBL] [Abstract][Full Text] [Related]
63. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
64. Severe secondary hyperparathyroidism in a chronic kidney disease patient treated with Radiofrequency ablation: One case report.
Muhetaer G; Liu G; Zhang L; Jiang H
Front Med (Lausanne); 2022; 9():876692. PubMed ID: 35935765
[TBL] [Abstract][Full Text] [Related]
65. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
[TBL] [Abstract][Full Text] [Related]
66. Combined use of a nanocarbon suspension and
Chen J; Zhou Q; Feng J; Wang J
Am J Otolaryngol; 2018; 39(2):138-141. PubMed ID: 29336900
[TBL] [Abstract][Full Text] [Related]
67. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
68. Ultrasound in clinical setting of secondary hyperparathyroidism.
Meola M; Petrucci I; Cupisti A
J Nephrol; 2013; 26(5):848-55. PubMed ID: 23042437
[TBL] [Abstract][Full Text] [Related]
69. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.
Tan W; Deng Q; Lin S; Wang Y; Xu G
Int J Hyperthermia; 2019; 36(1):264-272. PubMed ID: 30676100
[TBL] [Abstract][Full Text] [Related]
70. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
Reichel H
Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
[TBL] [Abstract][Full Text] [Related]
71. Long-term outcomes of microwave ablation for secondary hyperparathyroidism in maintenance hemodialysis patients.
Wang K; Gao Z; Liu S; Xiao L; Yao Z
Ther Apher Dial; 2021 Dec; 25(6):926-930. PubMed ID: 33675574
[TBL] [Abstract][Full Text] [Related]
72. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
74. Double phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism.
Piga M; Bolasco P; Satta L; Altieri P; Loi G; Nicolosi A; Tarquini A; Mariotti S
J Nucl Med; 1996 Apr; 37(4):565-9. PubMed ID: 8691240
[TBL] [Abstract][Full Text] [Related]
75. Surgical treatment of the parathyroid gland in patients with end-stage renal disease.
Albertucci M; Zielinski CM; Rothberg M; Sterpetti A; Klingman R; Ronk JF
Surg Gynecol Obstet; 1988 Jul; 167(1):49-52. PubMed ID: 3381185
[TBL] [Abstract][Full Text] [Related]
76. [Study of calcium-phosphorous metabolism and intact parathyroid hormone levels in end stage renal disease patients].
Sun LY; Wang M; Yang L
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 37(2):147-50. PubMed ID: 15841142
[TBL] [Abstract][Full Text] [Related]
77. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
[TBL] [Abstract][Full Text] [Related]
78. Subcutaneous injection is a simple and reproducible option to restore parathyroid function after total parathyroidectomy in patients with secondary hyperparathyroidism.
Ng JC; Wang W; Chua MJ; Tan MS; Tan NC; Soo KC; Tan HK; Iyer NG
Surgery; 2014 Apr; 155(4):682-8. PubMed ID: 24612625
[TBL] [Abstract][Full Text] [Related]
79. Persistent and recurrent hyperparathyroidism after total parathyroidectomy with autotransplantation.
Chou FF; Lee CH; Chen HY; Chen JB; Hsu KT; Sheen-Chen SM
Ann Surg; 2002 Jan; 235(1):99-104. PubMed ID: 11753048
[TBL] [Abstract][Full Text] [Related]
80. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
